INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies

E-ISSN： 1875-6646|7|1|33-38

ISSN： 1573-4072

Source： Current Bioactive Compounds, Vol.7, Iss.1, 2011-03, pp. : 33-38

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model

By Kratz Felix

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1743-1749

Springer Publishing Company

Access to resources Recommend Favorite

Safety, Pharmacokinetics and Biodistribution Studies of a β-galactoside Prodrug of Doxorubicin for Improvement of Tumor Selective Chemotherapy

By Devalapally Harikrishna Rajan Kombu Subramanian Akkinepally RaghuRam Rao Devarakonda Rama Krishna

Drug Development and Industrial Pharmacy, Vol. 34, Iss. 8, 2008-08 ,pp. : 789-795

Informa Healthcare

Access to resources Recommend Favorite

pKa, Zinc- and Serum Albumin-Binding of Curcumin and Two Novel Biologically- Active Chemically-Modified Curcumins

Current Medicinal Chemistry, Vol. 19, Iss. 25, 2012-09 ,pp. : 4367-4375

Bentham Science Publishers

Access to resources Recommend Favorite

Studies on Drug – Human Serum Albumin Binding: The Current State of the Matter

Current Pharmaceutical Design, Vol. 21, Iss. 14, 2015-04 ,pp. : 1817-1830

Bentham Science Publishers

Access to resources Recommend Favorite

Evaluation of the tumor targeting of a FAPαα-based doxorubicin prodrug

By Huang Sichao Fang Rui Xu Jun Qiu Shenghong Zhang Huan Du Jun Cai Shaohui

Journal of Drug Targeting, Vol. 19, Iss. 7, 2011-08 ,pp. : 487-496

Informa Healthcare

Access to resources Recommend Favorite